EU Approval and Product Identity

The European Union Executive Committee approved Ngenla (active ingredient: somatrogon) from Pfizer and OPKO Health on February 14, 2022, for the treatment of growth hormone deficiency in children and adolescents aged three years and older. The Committee for Medicinal Products for Human Use (CHMP) under the EMA adopted a positive opinion on December 16, 2021, and the marketing authorization holder is Pfizer Europe MA EEIG. Somatrogon is a long-acting growth hormone receptor agonist that combines a carboxy-terminal peptide of human chorionic gonadotropin beta-chain with human growth hormone. The key value of the approval lies in its ability to extend the half-life, allowing transition from daily injections of recombinant growth hormone to a weekly subcutaneous injection.

Clinical Basis and Patient Value

The approval is based on the global Phase 3 trial NCT02968004, which included 224 prepubertal children without prior treatment experience. Annual growth velocity was 10.10 cm in the Ngenla group and 9.78 cm in the daily somatropin group, with a least squares mean difference of 0.33 cm and a 95% confidence interval of -0.24 to 0.89 cm, meeting the non-inferiority criteria. Safety was generally similar to somatropin, although injection site reactions were more frequent with Ngenla. The interpretation that the product improves treatment burden and long-term adherence by reducing annual injections from approximately 365 to 52 is appropriate, rather than offering an absolute improvement in efficacy.

Competitive Landscape and Market Potential

The current standard of care includes daily injectable recombinant growth hormone, such as Pfizer's Genotropin (somatropin). Long-acting competitors include Novo Nordisk (NVO)'s Sogroya (somapacitan) and Ascendis Pharma (ASND)'s Skytrofa (lonapegsomatropin). According to OPKO's 2025 annual report, the global human growth hormone market size in 2024 was approximately USD 7.4 billion. Therefore, Ngenla's commercial success will be determined by reimbursement in different countries, pen usability, and price competition among weekly formulations, rather than clinical efficacy differentiation. Pfizer's existing Genotropin prescribing base provides an advantage in physician switching and distribution, but internal cannibalization must also be managed.

Global Regulatory and Partnership Economics

Ngenla was approved in Japan in January 2022, in the EU on February 14, 2022, and in the U.S. on June 27, 2023, for the treatment of pediatric growth hormone deficiency and is currently in the market. Pfizer secured exclusive global commercialization rights to somatrogon from OPKO in 2014, committing an upfront payment of USD 295 million and regulatory milestones up to USD 275 million. OPKO has fully achieved the USD 175 million pediatric growth hormone deficiency-related milestone and receives tiered gross profit sharing for Ngenla and Genotropin by region. The EU approval not only represents a single regulatory event but also reinforces the validation of OPKO's technology and the transition of Pfizer's growth hormone franchise to long-acting formulations.